Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention

International Journal of Cardiology

Volumn 205, Issue , 2016, Pages 50-53

  Konishi, Hirokazu ^a   Miyauchi, Katsumi ^a   Tsuboi, Shuta ^a   Ogita, Manabu ^a   Naito, Ryo ^a   Dohi, Tomotaka ^a   Kasai, Takatoshi ^a   Tamura, Hiroshi ^a   Okazaki, Shinya ^a   Isoda, Kikuo ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Lipoprotein(a); Percutaneous coronary intervention

Indexed keywords

LIPOPROTEIN A; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; EVENT FREE SURVIVAL; FEMALE; HEART DEATH; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; FOLLOW UP; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SURVIVAL RATE; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE;

EID: 84955473166     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.12.007     Document Type: Article

References (38)

1. A.S. Levey, J. Coresh, E. Balk, and et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann. Intern. Med. 139 2003 137 147
2. R.N. Foley, C. Wang, and A.J. Collins Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study Mayo Clin. Proc. 80 2005 1270 1277
3. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, and et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension 42 2003 1050 1065
4. J. Thambyrajah, M.J. Landray, F.J. McGlynn, H.J. Jones, D.C. Wheeler, and J.N. Townend Abnormalities of endothelial function in patients with predialysis renal failure Heart 83 2000 205 209
5. G.A. Kaysen, and J.P. Eiserich The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction J. Am. Soc. Nephrol. 15 2004 538 548
6. A.J. Collins, R.N. Foley, B. Chavers, and et al. United States renal data system 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States Am. J. Kidney Dis. 59 2012 A7 (e1-420)
7. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N. Engl. J. Med. 351 2004 1296 1305
8. D.E. Weiner, S. Tabatabai, H. Tighiouart, and et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease Am. J. Kidney Dis. 48 2006 392 401
9. P.J. Best, R. Lennon, H.H. Ting, and et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions J. Am. Coll. Cardiol. 39 2002 1113 1119
10. D.J. Blackman, R. Pinto, J.R. Ross, and et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention Am. Heart J. 151 2006 146 152
11. J.W. Jukema, J.J.W. Verschuren, T.A.N. Ahmed, and P.H.A. Quax Restenosis after PCI. Part 1: pathophysiology and risk factors Nat. Rev. Cardiol. 9 2012 53 62
12. E. Steyrer, S. Durovic, S. Frank, and et al. The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma J. Clin. Invest. 94 1994 2330 2340
13. H. Ikenaga, M. Ishihara, I. Inoue, and et al. Usefulness of lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction Circ. J. 75 2011 2847 2852
14. I. Kardys, R.M. Oemrawsingh, I.P. Kay, and et al. Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention Clin. Cardiol. 35 2012 482 489
15. C.P. Kovesdy, B.C. Astor, J.C. Longenecker, and J. Coresh Association of kidney function with serum lipoprotein(a) level: the third national health and nutrition examination survey (1991-1994) Am. J. Kidney Dis. 40 2002 899 908
16. M.D. Cressman, R.J. Heyka, E.P. Paganini, J. O'Neil, C.I. Skibinski, and H.F. Hoff Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients Circulation 86 1992 475 482
17. M.G. Shlipak, L.F. Fried, M. Cushman, and et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors JAMA 293 2005 1737 1745
18. S. Matsuo, E. Imai, M. Horio, and et al. Revised equations for estimated GFR from serum creatinine in Japan Am. J. Kidney Dis. 53 2009 982 992
19. A.K. Cheung, M.J. Sarnak, G. Yan, and et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients Kidney Int. 58 2000 353 362
20. K. Thygesen, J.S. Alpert, H.D. White, and et al. Universal definition of myocardial infarction Circulation 116 2007 2634 2653
21. A.S. Jaffe, J. Ravkilde, R. Roberts, and et al. It's time for a change to a troponin standard Circulation 102 2000 1216 1220
22. C.P. Cannon, R.G. Brindis, B.R. Chaitman, and et al. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College Of Cardiology Foundation/American Heart Association Task Force On Clinical Data Standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards) Circulation 127 2013 1052 1089
23. M. Chonchol, J. Whittle, A. Desbien, M.B. Orner, L.A. Petersen, and N.R. Kressin Chronic kidney disease is associated with angiographic coronary artery disease Am. J. Nephrol. 28 2008 354 360
24. J.H. Ix, N. Mercado, M.G. Shlipak, and et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS) Am. Heart J. 149 2005 512 519
25. K.M. Kostner, W. Marz, and G.M. Kostner When should we measure lipoprotein (a)? Eur. Heart J. 34 2013 3268 3276
26. R.A. Schwartzman, I.D. Cox, J. Poloniecki, R. Crook, C.A. Seymour, and J.C. Kaski Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris J. Am. Coll. Cardiol. 31 1998 1260 1266
27. S.W. Kwon, B.K. Lee, B.K. Hong, and et al. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients Int. J. Cardiol. 167 2013 1990 1994
28. F. Kronenberg, G. Utermann, and H. Dieplinger Lipoprotein(a) in renal disease Am. J. Kidney Dis. 27 1996 1 25
29. F. Kronenberg Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease Expert. Rev. Cardiovasc. Ther. 2 2004 729 743
30. K. Uhlig, S.R. Wang, G.J. Beck, and et al. Factors associated with lipoprotein(a) in chronic kidney disease Am. J. Kidney Dis. 45 2005 28 38
31. H.K. Aggarwal, D. Jain, M. Lathar, R.K. Yadav, and A. Sawhney Lipoprotein-a and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease Ren. Fail. 32 2010 647 652
32. G. Guz, F. Nurhan Ozdemir, S. Sezer, and et al. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients Am. J. Kidney Dis. 36 2000 826 836
33. V.M. Maher, and B.G. Brown Lipoprotein(a) and coronary heart disease Curr. Opin. Lipidol. 6 1995 229 235
34. D.J. Grainger, H.L. Kirschenlohr, J.C. Metcalfe, P.L. Weissberg, D.P. Wade, and R.M. Lawn Proliferation of human smooth muscle cells promoted by lipoprotein(a) Science 260 1993 1655 1658
35. J. Loscalzo, M. Weinfeld, G.M. Fless, and A.M. Scanu Lipoprotein(a), fibrin binding, and plasminogen activation Arteriosclerosis 10 1990 240 245
36. E. Boerwinkle, C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations J. Clin. Invest. 90 1992 52 60
37. C.P. Cannon, S. Shah, H.M. Dansky, and et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 363 2010 2406 2415
38. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J. Am. Coll. Cardiol. 59 2012 2344 2353